Corria-Osorio, Jesus http://orcid.org/0000-0001-6844-6170
Carmona, Santiago J. http://orcid.org/0000-0002-2495-0671
Stefanidis, Evangelos
Andreatta, Massimo http://orcid.org/0000-0002-8036-2647
Ortiz-Miranda, Yaquelin http://orcid.org/0000-0002-9136-6205
Muller, Tania
Rota, Ioanna A.
Crespo, Isaac
Seijo, Bili
Castro, Wilson http://orcid.org/0000-0002-9649-9883
Jimenez-Luna, Cristina http://orcid.org/0000-0002-2395-1728
Scarpellino, Leonardo
Ronet, Catherine
Spill, Aodrenn
Lanitis, Evripidis
Romero, Pedro http://orcid.org/0000-0002-9688-2882
Luther, Sanjiv A. http://orcid.org/0000-0002-8758-957X
Irving, Melita http://orcid.org/0000-0002-6849-7194
Coukos, George http://orcid.org/0000-0001-8813-7367
Article History
Received: 28 March 2022
Accepted: 1 March 2023
First Online: 20 April 2023
Competing interests
: G.C. has received grants and research support or is co-investigator in clinical trials by Bristol Myers Squibb, Celgene, Boehringer Ingelheim, Roche, Tigen Pharma, Iovance Biotherapeutics and Kite. Lausanne University Hospital (CHUV) has received honoraria for advisory services. G.C. has also received honoraria for advisory services provided to AstraZeneca, Bristol Myers Squibb, F. Hoffmann-La Roche, MSD Merck and Geneos Therapeutics. G.C. has patents in the domain of antibodies and vaccines targeting the tumor vasculature as well as technologies related to T-cell expansion and engineering for T-cell therapy. G.C. receives royalties from the University of Pennsylvania. J.C.-O. has patents in the domain of immune cytokines (TGF-β mutants) as well as in technologies related to T-cell expansion and engineering for T-cell therapy. The other authors declare no competing interests.